Aims Prevalence and clinical significance of right atrial enlargement (RAE) has been poorly characterized in hypertrophic cardiomyopathy.
Methods One hundred and sixty consecutive patients with hypertrophic cardiomyopathy (35.5 W 20 years; 64% men) were studied. They underwent clinical examination, standard ECG, M-mode, 2D and Doppler echocardiography, stress test and ECG Holter monitoring. Major adverse cardiac events were considered: cardiac death (sudden death, heart failure death); cardiac transplant; resuscitated cardiac arrest or appropriate implantable cardioverter defibrillator discharge. Genetic analysis of eight sarcomeric genes was performed using Sanger sequencing.
Results RAE was observed in 22 patients (14%), associated with left atrial enlargement in all cases. Patients with RAE were likely to have restrictive mitral pattern (P < 0.001) and had higher New York Heart Association (P < 0.001), N-terminal prohormone of brain natriuretic peptide (P < 0.001), left atrial volume index (P < 0.001), lateral (P U 0.04) and septal (P U 0.002) E/e 0 , systolic pulmonary artery pressure (P < 0.001) and lower ejection fraction (all P < 0.001). On cardiopulmonary exercise testing, peak VO 2 was lower and VE/VCO 2 higher in patients with RAE (P < 0.001). During a mean follow-up of 4 W 2.1 years, 30 major adverse cardiac events in 24 patients (15%) were observed. Cox proportional hazards regression analysis identified RAE as an independent predictor of major adverse cardiac events (odds ratio U 2.6; confidence interval 1.5-4.6; P U 0.001). In patients with RAE who were genetically tested, there was a higher prevalence of sarcomeric gene mutations (68%), double mutations (16%) and troponin T mutations (21%).
Conclusion RAE is present in a small subset of patients with hypertrophic cardiomyopathy, and largely reflects increased pulmonary pressures because of severe diastolic and/or systolic left ventricular dysfunction. Patients with RAE had a higher prevalence of sarcomeric gene mutations, troponin T mutations and complex genotypes. In conclusion, RAE may serve as a very useful marker of disease progression and adverse outcome in patients with sarcomeric hypertrophic cardiomyopathy.
Introduction
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, affecting approximately 1 : 500 individuals in the general population. [1] [2] [3] The clinical expression of HCM is heterogeneous, and the awareness of the diverse disease spectrum and clinical course has expanded substantially over the last decade. 4, 5 Most individuals with HCM remain asymptomatic, but someone can experience progressive exercise intolerance and heart failure symptoms, and unexpected sudden cardiac death can occur at any age. [6] [7] [8] Left atrial enlargement (LAE) has been shown to be a sensitive marker of filling pressures and adverse prognosis in HCM. 9, 10 Right atrial enlargement (RAE) has been less well investigated in HCM. In this study, we sought to characterize prevalence, clinical significance and genetic epidemiology of RAE in HCM. We hypothesized that RAE represents a marker of disease severity, and thus measurement of right atrial size by conventional echocardiography may provide additional prognostic information in patients with HCM.
Methods

Patient population
The present study is an observational cross-sectional cohort study, including patients with HCM seen from 2001 to 2011. All patients were from southern Italy and were of Caucasian descent. HCM was defined as unexplained left ventricular hypertrophy (wall thickness of >15 mm in adults; z-score value >2 in children). As previously described, syndromic (n ¼ 34), metabolic (n ¼ 4), infiltrative (n ¼ 2) and neuromuscular (n ¼ 5) disorders associated with HCM were excluded following a standard protocol using noninvasive and, when necessary, invasive investigations (muscle biopsy, fat/rectal biopsy and endomyocardial biopsy).
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Study protocol All patients underwent a complete cardiovascular evaluation, including family and personal history, physical examination, blood tests including N-terminal prohormone of brain natriuretic peptide measurement, 12-lead ECG at rest, conventional M-mode, two-dimensional and Doppler echocardiography, 24-h Holter ECG and treadmill or cardiopulmonary exercise testing. New York Heart Association (NYHA) class based on the degree of dyspnoea or exercise limitation was evaluated to define the severity of heart failure. Nonsustained ventricular tachycardia during 24 h ambulatory ECG monitoring was defined as three or more consecutive ventricular beats at a rate of at least 120 beats/min, lasting for less than 30 s. An abnormal blood pressure response during exercise was defined as initial increase in SBP with a subsequent fall of more than 20 mmHg compared with the blood pressure value at peak exercise or a continuous decrease in SBP throughout the exercise test of more than 20 mmHg compared with resting blood pressure or an increase of less than 20 mmHg in SBP from resting state to peak exercise. 12 A clinical evaluation including standard ECG and echocardiography was generally repeated every 6 months. An ECG Holter and an exercise test were generally performed at least once a year. Genetic analysis was performed after obtaining informed consent, according to the procedure established by the ethic committee of our institution.
Echocardiographic evaluation
Left ventricular end-diastolic and end-systolic diameters and shortening fraction, end-diastolic thicknesses of interventricular septum and left ventricular posterior wall were obtained from M-mode echocardiograms, according to recommendations of the American Society of Echocardiography. 13 At two-dimensional echocardiography, sites and maximal extent of ventricular hypertrophy were assessed in enddiastole by parasternal short-axis view. Left ventricular end-diastolic and end-systolic volumes and ejection fraction were calculated from apical views, using the biplane method of discs (modified Simpson's rule). An ejection fraction of less than 50% was considered abnormal. Left atrial volume index was measured using the biplane area-length method. The maximal left atrial area was measured in apical four and two-chamber views by tracing the endocardial border, excluding the confluence of the pulmonary veins as well as the left atrial appendage.
Left atrial length was measured from the midline of the plane of the mitral annulus to the opposite superior aspect of the left atrium. The measurements were performed at end-systole from the frame immediately preceding mitral valve opening. Left atrial volume greater than 34 ml/m 2 was consider as LAE.
14 Right atrium (RA) area was calculated by planimetry (tracing the endocardium, and paying attention to exclude the possible redundancy of the great vein valves) in the apical four-chamber view at the point of tricuspid valve opening, and was corrected for height (RA area index), as previously reported. 15 RA area greater than 18 cm 2 was considered as RAE. 16 Systolic intraventricular gradients were assessed using continuous wave Doppler. A systolic peak gradient greater than 30 mmHg, at rest or after a Valsalva maneuver, was considered abnormal.
Left ventricular diastolic function was assessed by pulsed Doppler at the level of mitral tips. Peak flow velocity in early diastole and during atrial contraction, and E/A ratio were measured, as well as deceleration time of early diastolic flow velocity. The pattern of left ventricular filling was classified as: restrictive if deceleration time less than 120 ms or E/A of at least 2 associated with deceleration time of 150 ms or less; abnormal relaxation if E/A less than 1 associated with deceleration time of at least 220 ms; normal (or 'pseudonormal') filling in presence of intermediate patterns. 17 In patients with atrial fibrillation, only E wave and deceleration time were measured. Systolic, early diastolic (e 0 ), and late diastolic tissue Doppler velocities were measured at the lateral mitral and septal walls and subsequently averaged over three cardiac cycles in accordance with previously reported methods. 18 Transmitral E/e 0 ratios (lateral, septal, average) were calculated for each patient. E/e 0 average ratio was considered increased if higher than 15.
Clinical events
Sudden cardiac death was defined as unexpected sudden collapse within 1 h of onset of symptoms occurring in patients who had previously experienced a relatively stable or uneventful clinical course. Heart failure-related death was defined as death occurring in the context of cardiac decompensation and progressive disease course 1 year or more before death.
End-stage evolution was defined as the development of hypokinetic left ventricle with a left ventricular ejection fraction of less than 50%. In patients who had already presented at our center with a dilated and/or hypokinetic left ventricle, diagnosis of HCM always included previous echocardiographic documentation of classic HCM and family screening.
Major adverse cardiac events (MACE) were considered: cardiac death (sudden death, death from heart failure); cardiac transplant; resuscitated cardiac arrest ('aborted sudden death') or appropriate implantable cardiac defibrillator discharge.
Genetic analysis
All exons, including the splicing sites, and 5 0 and 3 0 -untranslated regions of the beta-myosin heavy chain, myosin-binding protein C, troponin T, troponin I, alphatropomyosin, regulatory myosin light chain, essential myosin light chain, alpha-cardiac actin, protein kinase, AMP-activated, gamma 2 and lysosomal-associated membrane protein 2 were amplified by PCR, as previously described. PCR products were then examined for sequence variations by Sanger sequencing. Nucleotide positions were numbered on the basis of the cDNA sequence according to the den Dunnen and Antonarakis nomenclature. 19 When sequence variation was detected, the patient's available relatives underwent genetic screening.
Statistical analysis
Statistical analysis was performed using a commercially available package (SPSS, version 15.0, 2002, SPSS Inc., Chicago, Illinois, USA). Data are presented as percentages, or means and standard deviations. Categorical variables were compared using the Fisher exact test or the x 2 statistic. Two groups of normally distributed variables were compared using the Student's t-test, and analysis of variance was used to compare more than two groups. Skewed data were analyzed using the MannWhitney U test, the Wilcoxon rank-sum test and the Kruskal-Wallis test, as appropriate. Linear regression and logistic, stepwise, multivariable models were performed to analyze predictors of RAE (baseline) and RA remodeling (during follow-up). For the survival analysis, the start of follow-up was defined as the first cardiovascular evaluation at Monaldi Hospital. Variables selected by univariate statistic (P < 0.01) were selected for a multivariable Cox regression as an interactive stepwise backward elimination method, each time excluding the one variable with the highest P-value according to Wald statistics. The assumption of linearity was checked graphically by studying the smoothed martingale residuals from the null model plotted against the covariate variables. The linearity assumptions were satisfied. The Hosmer-Lemeshow goodness-of-fit test was used to check that the model adequately fitted the data. In order to decrease the inflation of the type 1 error rate due to multiple testing, the statistical significance was defined as two-sided P-value <0.01.
Results
Study population
The study cohort comprised 160 consecutive patients. The mean age at the first evaluation was 35.5 AE 20 years (age ranging from birth to 74 years); 103 (64%) patients were men. Family history of HCM was present in 84 patients (53%), whereas family history of sudden cardiac death was present in 43 patients (27%). The diagnosis was based on symptoms in 75 patients (47%), incidental finding in 57 patients (35.5%) and family screening in 28 patients (17.5%). RAE was observed in 22 patients (13.7%), and was always associated with LAE (biatrial enlargement). Table 1 shows a comparison of clinical characteristics of patients with HCM with (n ¼ 22) and without (n ¼ 138) RAE. Moderate to severe diastolic dysfunction and elevated noninvasive wedge/systolic pulmonary pressure were observed in almost all patients with RAE, compared with no RAE patients (P < 0.0001). Four patients (18%) had an end-stage disease (i.e. hypokinetic evolution; ejection 50%). Two patients had a cardiac arrest (at disease onset or in the first month after the first evaluation). A logistic, stepwise forward, multivariate model including all the significant variables at univariate analysis demonstrated that systolic pulmonary artery pressure of at least 30 mmHg [P ¼ 0.025; odds ratio (OR) 1.1; 95% confidence interval (CI) 1-1.2] and NYHA class at least 2 (P ¼ 0.05; OR ¼ 3.9; 95% CI 1.5-13) were independent predictors of RAE.
Follow-up and cardiac events
Clinical events are reported in Table 2 . During a mean follow-up of 4 AE 2.1 years, a cardioverter defibrillator was implanted in 24 (15%) and an appropriate discharge occurred in three patients (1.9%). Seventeen patients experienced heart failure episodes requiring hospitalization, including eight with RAE (five patients with ejection fraction <50%) and nine without RAE (seven with ejection fraction <50%). Stroke events were more frequent in patients with (14%) than patients without (<1%) RAE. Four patients in the RAE cohort (18%) were listed for transplant: three of them underwent successful orthotopic heart transplant and one patient underwent ventricular assist device implantation. Six patients, in the entire cohort, died. The cause of death was sudden in one patient in each group (HCM with or without RAE). Two patients, one from each group, died from complications soon after heart transplant surgery. The patient who underwent ventricular assist device implantation died of multiorgan failure after 1 week. One patient with HCM without RAE died from noncardiac causes. Cox proportional hazards regression analysis, with clinical and echocardiographic variables significant at x 2 analysis and univariate binomial model (including ejection fraction <50%, atrial fibrillation, restrictive filling pattern, septal E/e 0 > 15) identified RAE (as a time-dependant covariate) as an independent predictor of MACE (OR ¼ 2.6; 95% CI 1.5-4.6; P ¼ 0.001). Figure 1 shows a comparison of survival free of MACE between patients with RAE (RAE; n ¼ 22; 14%), patients with isolated LAE (n ¼ 101; 63%) and patients with no signs of atrial enlargement (n ¼ 37; 23%; P ¼ 0.0001).
Genetic results and genotype-phenotype correlation Genetic investigation has been completed for 94 of 160 patients with HCM: sequencing analysis of 10 genes identified a total of 61 mutations in 52 independent patients with HCM (overall prevalence 55.3%). Of these, 59 (97%) mutations have been previously reported as associated with HCM phenotype, whereas two (3%) were novel variants. Novel mutations are absent from any publicly available databases (ESP and dbSNP137, that also includes the 1000 Genome Project data, MAF ¼ 0) and are considered pathogenetic by in-silico functional prediction using bioinformatics programs (http://genetics.bwh.harvard.edu/pph/; http://sift.jcvi.org/; http://neu rocore.charite.de/MutationTaster, for coding variants; a specific software Alamut 2.0 was used to search for splicing prediction).
When we separated genotyped HCM patients with RAE (n ¼ 20) from patients without RAE (n ¼ 74) prevalence of sarcomeric mutations was significantly higher in the first group (85 vs. 50.3%; P < 0.004.) Molecular epidemiology, with respect to eight sarcomeric genes and LAMP and PRKAG2, was different between the two groups as regards TNNT2 mutations (20% in HCM with RAE vs. 3.7% in patients without RAE, P ¼ 0.016). Overall, eight patients (8.5%) had a complex genotype, characterized by double-gene mutation heterozygosis (n ¼ 4; 4.2%), compound heterozygosis (n ¼ 3; 3.2%) and homozygosis (n ¼ 1; 1%). Also complex genotypes were more frequent in patients with HCM with RAE (20 vs. 5.3% in patients without RAE, although it is not statistically different, P ¼ 0.058, Fig. 2 ).
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6 (27.3%) 18 (13%) 0.08 Heart failure episodes (n, %) 8 (36.3%) 9 (6.5%) <0.0001 Heart transplant/VAD (n, %) 4 (18%) 1 (0.7%) <0.0001 Appropriate ICD discharge (n, %) 1 (4.5%) 2 (1%) / Sudden death (n, %) 1 (4.5%) 1 (0.7%) / Cardiac death (n, %) 2 (9%) 1 (0.7%) / Non-cardiac death (n, %) / 1 (0.7%) / ICD, implantable cardioverter defibrillator; RAE, right atrial enlargement; VAD, ventricular assist device. Cumulative risk for adverse outcome in patients with classic hypertrophic cardiomyopathy, patient with no atrial dilation, isolated left atrial enlargement and patients with right atrial enlargement. Major adverse cardiac events were defined as combined end point including death, heart transplant/transplant list and aborted sudden death/ appropriate implantable cardioverter defibrillator discharge. LAE, left atrial enlargement; MACE, major adverse cardiac events; RAE, right atrial enlargement.
Discussion
The present study analyzed for the first time prevalence, clinical significance and genetic background of RAE in a relatively large cohort of patients with HCM. The main findings of the study were the occurrence of RAE in a small subgroup (14%) of patients with HCM; the association of RAE with MACE and a high prevalence of sarcomeric mutations, TNNT2 mutations and complex genotypes in patients with RAE.
Clinical significance of right atrial enlargement HCM is characterized by heterogeneous phenotypic expression. This affects the presence, degree and localization of myocardial hypertrophy, disarray and fibrosis; the presence, severity and site of intracavitary obstruction; the presence and severity of diastolic and systolic dysfunction and natural history and clinical outcome. 20 Heart failure symptoms in patients with HCM are mainly related to left ventricular outflow tract obstruction, diastolic dysfunction (heart failure with preserved ejection fraction) and systolic dysfunction (heart failure with reduced ejection fraction). 21 Left ventricular outflow tract obstruction, LAE, restrictive physiology and reduced ejection fraction (<50%) are known to be associated with adverse prognosis in HCM. [22] [23] [24] 'Restrictive physiology' is generally evaluated by noninvasive echocardiographic indices, such as transmitral and pulmonary flow velocities, and by using tissue Doppler measurements such as diastolic mitral annulus velocities (E/e 0 ratio). However, these indices show only a modest correlation with the invasive measurement of left atrial and wedge pressure by cardiac catheterization, and their reproducibility is low in presence of atrial fibrillation and in the late stages of the disease. 25 The measurement of right atrial size by conventional echocardiography is relatively easy and reproducible, even in presence of atrial fibrillation and in the end-stage phase of the disease. However, the additional prognostic value of right atrial size measurements has not been analyzed, so far. In this study, patients with RAE were more symptomatic, had more severe exercise limitation, greater N-terminal prohormone of brain natriuretic peptide elevation, elevated systolic pulmonary artery pressure and presence of advanced diastolic and/or systolic dysfunction. In this study, RAE seems a good marker of end-stage progression, and largely reflects increased pulmonary pressures due to severe left ventricular dysfunction (which may be purely diastolic or systo-diastolic). Thus, RAE may serve as a very useful marker of disease progression toward the end-stage phase. In clinical practice, RAE is generally considered a surrogate of severe restrictive physiology and pulmonary hypertension. However, a subset of patients had only mild diastolic abnormalities, suggesting that RAE may represent a relatively early marker of a 'restrictive phenotype', preceding a clinically evident 'restrictive physiology.' Thus, measurement of RA size may be of help to guide clinical management of patients with nonobstructive HCM, particularly when evaluation of systolic and diastolic function is complicated by atrial fibrillation.
Supportive evidence for this comes from a postmortem study by Melacini et al. 26 looking at HCM patients who developed severe progressive heart failure. Interestingly, patients with nonobstructive HCM and RAE deteriorated to advanced NYHA classes III-IV associated with diastolic dysfunction or atrial fibrillation, compared with other HCM groups. Pathological examination of gross heart specimens showed small ventricular cavities, markedly enlarged atria, only focal scars of myocardial fibrosis and mild left ventricular hypertrophy.
Genetic epidemiology and pathogenesis of right atrial enlargement The presence of RAE phenotype was associated with a higher frequency of mutations in sarcomeric genes (68 vs. 43%). A higher frequency of double mutations (16 vs. 0%) was also observed. Recently, Biagini et al. 27 studied a large cohort of end-stage HCM patients and found complex genotypes with double or triple mutations in 13% compared with 5% of the reference cohort (P ¼ 0.01). However, as in the present study, the outcome of endstage HCM was independent of genotype. There was also a relatively high percentage of troponin T mutations. Of note, three patients with troponin T mutations had cardiac arrest (H11, H43, H133), whereas patient H133 has been listed for heart transplant. However, given the relatively small cohort of patients studied, it is not possible to analyze a potential correlation between genotype and outcome in this subgroup.
The mechanism of RAE is unknown. Progressive diastolic dysfunction and atrial fibrillation may represent adequate substrates for right atrial remodeling. A progressive 'atrial myopathy' has also been suggested in patients with HCM. 28 A genetic basis of RAE is an attractive hypothesis, although it is likely that the atrial remodeling is a complex phenotype requiring both genetic (i.e. double mutations) and nongenetic (hemodynamic) effects.
Study limitations
Although our study population and the number of clinical events are relatively small, this is the first study to analyze prevalence and potential clinical impact of RAE in HCM. Recent guidelines recommend the use of RA volume as the gold standard to measure RA size. 13 This study was conducted before 2015, and RA size was measured as suggested by previous guidelines. 16 Only few patients underwent cardiac catheterization, with invasive estimation of left ventricular end-diastolic pressure and left/right atrial pressure measurements (n ¼ 5). However, the correlation between the Doppler-derived diastolic parameters (transmitral Doppler flow velocities and mitral annular velocities) and invasive measurements measurement was behind the scope of the study.
Conclusion
RAE is present in a small subset of patients with HCM, and largely reflects increased pulmonary pressures due to severe diastolic and/or systolic left ventricular dysfunction. Patients with RAE had a higher prevalence of sarcomeric gene mutations, troponin T mutations and complex genotypes. In conclusion, RAE may serve as a very useful marker of disease progression and adverse outcome in patients with sarcomeric HCM.
